| 12.01 0.75 (6.66%) | 11-27 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 33.47 | 1-year : | 39.09 |
| Resists | First : | 28.65 | Second : | 33.47 |
| Pivot price | 24.01 |
|||
| Supports | First : | 20.47 |
Second : | 15.4 |
| MAs | MA(5) : | 27.18 |
MA(20) : | 23.35 |
| MA(100) : | 15.39 |
MA(250) : | 11.48 |
|
| MACD | MACD : | 2.3 |
Signal : | 2 |
| %K %D | K(14,3) : | 83  |
D(3) : | 85.3 |
| RSI | RSI(14): 72.1 |
|||
| 52-week | High : | 28.65 | Low : | 2.66 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ AGLE ] has closed below upper band by 14.5%. Bollinger Bands are 60% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 28.03 - 28.13 | 28.13 - 28.22 |
| Low: | 26.47 - 26.59 | 26.59 - 26.7 |
| Close: | 27.3 - 27.51 | 27.51 - 27.67 |
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Tue, 28 Nov 2023
SYRE Stock Price and Chart — NASDAQ:SYRE — TradingView - TradingView
Mon, 27 Nov 2023
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and ... - PR Newswire
Thu, 09 Nov 2023
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update - PR Newswire
Wed, 01 Nov 2023
Aeglea BioTherapeutics Announces Grants of Inducement Awards - PR Newswire
Thu, 07 Sep 2023
Aeglea BioTherapeutics Announces Reverse Stock Split - Yahoo Finance
Thu, 27 Jul 2023
Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 1.92e+006 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 114 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.884e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -9 % |
| Return on Assets (ttm) | 485 % |
| Return on Equity (ttm) | -41.9 % |
| Qtrly Rev. Growth | 1.05e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -109.5 |
| EBITDA (p.s.) | -101946 |
| Qtrly Earnings Growth | -74.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -87 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.26 |
| Price to Cash Flow | -1.17 |
| Dividend | 0 |
| Forward Dividend | 139690 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|